Updates on Clinical Studies and Milestone Revenues - Research Report on Cyberonics, West, Nektar, OraSure, and Akorn

   Updates on Clinical Studies and Milestone Revenues - Research Report on
                 Cyberonics, West, Nektar, OraSure, and Akorn

PR Newswire

NEW YORK, November 12, 2013

NEW YORK, November 12, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting
Cyberonics, Inc. (NASDAQ: CYBX), West Pharmaceutical Services, Inc. (NYSE:
WST), Nektar Therapeutics (NASDAQ: NKTR), OraSure Technologies, Inc. (NASDAQ:
OSUR), and Akorn, Inc. (NASDAQ: AKRX). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Cyberonics, Inc. Research Report

On November 7, 2013, Cyberonics, Inc. (Cyberonics) announced that it will
release its Q2 FY 2014 financial results (period ended October 25, 2013) on
November 21, 2013, before regular market trading hours. On the same day, the
Company will host a conference call at 8:00 a.m. CT / 9:00 a.m. ET to discuss
the results. The Full Research Report on Cyberonics, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/ad51_CYBX]

West Pharmaceutical Services, Inc. Research Report

On November 7, 2013, West Pharmaceutical Services, Inc. (West) announced that
it has completed a preliminary study of its SmartDose technology platform,
incorporating a Daikyo Crystal Zenith (CZ) cartridge. The Company informed
that the study evaluated multiple attributes of the technology and subjects'
experience with the self-application process. "We believe our efforts to
develop the SmartDose technology platform system are important, because we see
an unmet need for high-volume subcutaneous delivery of viscous or sensitive
drug products, which may require longer injection times," said Paul Norton,
Vice President of Self-Injection Systems at West. Norton continued, "The
flexibility of CZ allows it to be optimized for use with the SmartDose
platform and makes it possible to utilize these technologies for the next
generation of self-administered protein-based drugs. This is an important step
as we seek to develop a complete drug delivery system incorporating the
benefits of Daikyo CZ as an alternative to glass for biotech products." The
Full Research Report on West Pharmaceutical Services, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/39a2_WST]

Nektar Therapeutics Research Report

On November 7, 2013, Nektar Therapeutics (Nektar) reported Q3 2013 financial
results. In Q3 2013, the Company generated revenues of $60.9 million, up
229.7% YoY, primarily due to a $25.0 million milestone related to the
acceptance of the naloxegol MAA filing in Europe and increase in products
sales. For Q3 2013, net loss was $16.5 million, or $0.14 per diluted share,
compared with a net loss of $43.5 million, or $0.38 per diluted share, in Q3
2012. "Nektar continues to have a very productive year achieving significant
milestones with both our partnered programs and proprietary pipeline," said
Howard W. Robin, President and CEO of Nektar. "For naloxegol, the MAA in
Europe and NDS in Canada are now accepted for filing and the NDA in the U.S.
was submitted for filing in mid-September. Naloxegol could be the first
once-daily oral peripheral opioid antagonist approved to treat opioid-induced
constipation. BAX 855, Baxter's longer-acting PEGylated Factor VIII therapy,
which is in Phase 3, remains on track for a 2014 BLA filing." The Full
Research Report on Nektar Therapeutics - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.analystscorner.com/r/full_research_report/3421_NKTR]

OraSure Technologies, Inc. Research Report

On November 6, 2013, OraSure Technologies, Inc. (OraSure) reported Q3 2013
financial results. In Q3 2013, consolidated net revenues were $24.7 million,
up 11.6% YoY, primarily due to sales of OraQuick In-Home HIV test, as well as
record revenues from DNA Genotek, OraSure's molecular collection systems
subsidiary. In Q3 2013, consolidated net loss was $1.9 million, or $0.03 per
diluted share, compared with a net loss of $2.4 million, or $0.04 per diluted
share, in Q3 2012. "Our molecular collection systems business continues to
deliver strong growth and we are encouraged by the higher sales of our
OraQuick® HCV test. We have also launched a new targeted promotional campaign
for the OraQuick® In-Home HIV test in an effort to accelerate growth of that
important product line," said Douglas A. Michels, President and CEO of
OraSure. The Full Research Report on OraSure Technologies, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/ef88_OSUR]

Akorn, Inc. Research Report

On November 5, 2013, Akorn, Inc. (Akorn) reported Q3 2013 financial results.
In Q3 2013, the Company achieved record consolidated revenues of $81.9
million, up 17.6% YoY due to the sales of new products that were launched in
late 2012, as well as increases in sales volume for existing products, offset
by decreases in the average sales price for existing products and lower sales
from the Company's subsidiary in India. For Q3 2013, net income was $12.2
million, or $0.11 per diluted share, compared with $13.8 million, or $0.12 per
diluted share, in Q3 2012. "We are pleased with our third quarter results as
we continue to demonstrate a strong double-digit growth rate in our top-line
despite the delays in getting regulatory approvals from the U.S. Food and Drug
Administration. In addition, we had a solid quarter of earnings and cash flow.
We continue to build our pipeline with the increased investment in R&D and are
excited about the acquisition of Hi-Tech which we expect to close in the first
quarter of 2014. We expect to have a strong finish to the year 2013 as we
expect to be at the upper end of our current revenue guidance," said Raj Rai,
CEO of Akorn. The Full Research Report on Akorn, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/900c_AKRX]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to making mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.analystscorner.com/

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.